首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1378549

膽管癌市場：依癌症類型、治療類型、給藥途徑、配銷通路及地區分類

Cholangiocarcinoma Market, By Cancer Type, By Therapy Type, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2023年10月20日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年全球膽管癌市場規模為4.232億美元，預計到2030年將達到160.7萬美元，在預測期內（2023-2030年）年度成長20.9%，預計呈現平均成長率（年複合成長率）。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	4.232 億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	20.90%	2030年市場規模預測	16.7億美元

圖 1. 2023 年按治療類型分類的膽管癌全球市場佔有率(%)

膽管癌，也稱為膽管癌，是一種始於膽管的癌症。膽管癌是一種比較罕見的癌症，而且癌症的症狀往往要到晚期才會出現，所以必須在階段才被診斷出來。膽管癌的確切病因尚不清楚，但膽管慢性發炎、某些感染疾病（如肝流感寄生蟲）和某些危險因子（如吸煙和酗酒）等因素可能導致這種癌症。它被認為會增加發育風險。診斷通常涉及影像檢查（例如電腦斷層掃描、MRI 或內視鏡逆行性胰造影(ERCP)）與組織切片檢查的結合，以確認癌症的存在。膽管癌的治療方法根據癌症的階段和患者的一般狀況而有所不同。治療方法包括手術、放射線治療、化療和其他標靶治療。膽管癌的預後因診斷階段而異，早期發現和介入對於改善預後至關重要。

市場動態

主要企業正在進行研發活動，預計這將在預測期內推動全球膽管癌市場的成長。例如，2022 年 2 月，德國臨床研究機構 Krankenhaus Nordwest 的 Institut Fur Klinische Krebsforschung IKF GmbH 宣布「durvalumab 和 tremelimumab 聯合或不聯合卡培他濱用於膽道癌的輔助性治療」。名為「第二階段免疫療法試驗”的臨床試驗。該研究目前處於第二階段，預計將於 2024 年 12 月完成。

本次測試的主要特點

本報告詳細分析了全球膽管癌市場，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率(CAGR)。
它還闡明了不同細分市場的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球膽管癌市場的主要企業。
該報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場經營團隊和行銷策略做出資訊的決策。
全球膽管癌市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球膽管癌市場的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- BridgeBio Inc.
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE &Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson &Johnson Private Limited
- Bliss Biopharmaceutical
- Novartis AG
- LES LABORATOIRES SERVIER
- F.Hoffmann-La Roche Ltd
- Mylan NV（Viatris.Inc）
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
分析師觀點

第11章章節

參考
調查方法

簡介目錄

Product Code: CMI4435

Global Cholangiocarcinoma market is estimated to be valued at US$ 423.2 Mn in 2023 and is expected to reach US$ 1,600.7 Mn by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 20.9% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 423.2 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	20.90%	2030 Value Projection:	US$ 1,600.7 Mn

Figure 1. Global Cholangiocarcinoma Market Share (%), By Therapy Type, 2023

Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that originates in the bile ducts. Cholangiocarcinoma is a relatively rare cancer which needs to be diagnosed at an advanced stage because the symptoms of the cancer often appears late until the disease is at its well-advanced stage. The exact cause of cholangiocarcinoma is unknown, but it is believed that factors such as chronic inflammation of the bile ducts, certain infections (e.g., with the liver fluke parasite), and certain risk factors (e.g., smoking, heavy alcohol use) may increase the risk of developing this cancer. Diagnosis typically involves a combination of imaging studies, such as CT scans, MRIs, and endoscopic retrograde cholangiopancreatography (ERCP), as well as tissue biopsies to confirm the presence of cancer. Treatment options for cholangiocarcinoma depends on the stage of the cancer and the patient's overall health. The treatments are surgery, radiation therapy, chemotherapy, and other targeted therapies. Prognosis for cholangiocarcinoma varies depending on the stage at which it is diagnosed, and early detection and intervention are crucial for improving outcomes.

Market Dynamics

Key players are engaged in research and development activities which is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, in February 2022, Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, a Germany-based clinical research institution, initiated a clinical trial titled "A Phase II Study of Immunotherapy with Durvalumab and Tremelimumab in Combination with Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer". The study is currently in phase 2 which is estimated to get completed by December 2024.

Key features of the study:

This report provides an in-depth analysis of the global cholangiocarcinoma market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cholangiocarcinoma market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include BridgeBio Inc., Sanofi, Eisai Co., Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Incyte, TRISALUS LIFE SCIENCES, INC., GENFIT, Johnson & Johnson Private Limited, Bliss Biopharmaceutical, Novartis AG, LES LABORATOIRES SERVIER, F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris.Inc), AstraZeneca, Compass Therapeutics, Inc, Otsuka Holdings Co., Ltd., and Senhwa Biosciences, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market

Detailed Segmentation:

Global Cholangiocarcinoma Market, By Cancer Type:
- Perihilar
- Distal
- Extrahepatic Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma
Global Cholangiocarcinoma Market, By Therapy Type:
- Targeted Drug Therapy
- Pemigatinib
- Ivosidenib
- Futibatinib
- Infigratinib
- Chemotherapy
- 5-fluorouracil
- Gemcitabine
- Cisplatin
- Capecitabine
- Oxaliplatin
- Immunotherapy
- Pembrolizumab
- Others (Late phase pipeline drugs)
- Others (Pain Medications and others)
By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- BridgeBio Inc.
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Novartis AG
- LES LABORATOIRES SERVIER
- F. Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Cancer Type
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Recent Product Launches/Approvals
Recent Trends
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Cholangiocarcinoma Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Cholangiocarcinoma Market, By Cancer Type, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Extrahepatic Cholangiocarcinoma
Perihilar
Distal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Intrahepatic Cholangiocarcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

6. Global Cholangiocarcinoma Market, By Therapy Type, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Targeted Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Pemigatinib
Ivosidenib
Futibatinib
Infigratinib
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
5- fluorouracil
Gemcitabine
Cisplatin
Capecitabine
Oxaliplatin
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Pembrolizumab
Others (Late phase pipeline drugs)
Others (Pain Medications and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

7. Global Cholangiocarcinoma Market, By Route of Administration, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Oral
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Subcutaneous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Intravenous
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends

8. Global Cholangiocarcinoma Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

9. Global Cholangiocarcinoma Market, By Region, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Market Size and Forecast, and By Y-o-Y Growth, By Region, 2018 - 2030, (US$ Mn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- BridgeBio Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Sanofi
- Eisai Co., Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Fresenius SE & Co. KGaA
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Incyte
- TRISALUS LIFE SCIENCES, INC.
- GENFIT
- Johnson & Johnson Private Limited
- Bliss Biopharmaceutical
- Novartis AG
- LES LABORATOIRES SERVIER
- F.Hoffmann-La Roche Ltd
- Mylan N.V. (Viatris.Inc)
- AstraZeneca
- Compass Therapeutics, Inc
- Otsuka Holdings Co., Ltd.
- Senhwa Biosciences, Inc.
Analysts' Views

11. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

膽管癌治療藥的全球市場調查報告-產業分析，規模，佔有率，成長，趨勢，2022年～2028年前的預測

FAQ

膽管癌市場：依癌症類型、治療類型、給藥途徑、配銷通路及地區分類